Thioredoxin reductase-1 and incidence of COVID-19 among cholangiocarcinoma patients in tropical endemic area
Author:
- 15 February 2022
- journal article
- letter
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 19 (3) , 845
Abstract
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic SocietyKeywords
This publication has 5 references indexed in Scilit:
- Understanding Selenium and Glutathione as Antiviral Factors in COVID-19: Does the Viral Mpro Protease Target Host Selenoproteins and Glutathione Synthesis?Frontiers in Nutrition, 2020
- Cancerous Patient with COVID-19: Note on Data from the first 3-Month Period of DiseaseSouth Asian Journal of Cancer, 2020
- Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study [J Epidemiol 29 (5) (2019) 197–204]Journal of Epidemiology, 2020
- Characterization of the antioxidant enzyme, thioredoxin peroxidase, from the carcinogenic human liver fluke, Opisthorchis viverriniMolecular and Biochemical Parasitology, 2008
- Clinical findings among 62 Thais with cholangiocarcinomaTropical Medicine & International Health, 2003